Open access · OA
via OpenAlex
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
Matthias Waldner, Daniel Fantus, Mario G. Solari, Angus W. Thomson
British Journal of Clinical Pharmacology · 2016 · ▲ 99 citations
Abstract
The macrolide mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) and its analogues (rapalogs) constitute the first generation of mammalian target of rapamycin (mTOR) inhibitors. Since the introduction of rapamycin as an immunosuppressant, there has been extensive progress in understanding its complex mechanisms of action. New insights into the function of mTOR in different immune cell types, vascular endothelial cells and neoplastic cells have opened new opportunities and challenges regarding mTOR as a pharmacological target. Currently, the two known mTOR complexes, mTOR complex (mTORC) 1 and mTORC2, are the subject of intense investigation, and the introduction of second-generation dual mTORC kinase inhibitors (TORKinibs) and gene knockout mice is helping to uncover the distinct roles of these complexes in different cell types. While the pharmacological profiling of rapalogs is advanced, much less is known about the properties of TORKinibs. A potential benefit of mTOR inhibition in transplantation is improved protection against transplant-associated viral infections compared with standard calcineurin inhibitor-based immunosuppression. Preclinical and clinical data also underscore the potentially favourable antitumour effects of mTOR inhibitors in regard to transplant-associated malignancies and as a novel treatment option for various other cancers. Many aspects of the mechanisms of action of mTOR inhibitors and their clinical implications remain unknown. In this brief review we discuss new findings and perspectives of mTOR inhibitors in transplantation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/bcp.12893
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Waldner, M., Fantus, D., Solari, M.G., & Thomson, A.W. (2016). New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. <em>British Journal of Clinical Pharmacology</em>. https://doi.org/10.1111/bcp.12893
Vancouver
Waldner M, Fantus D, Solari MG, Thomson AW. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. British Journal of Clinical Pharmacology. 2016. doi:10.1111/bcp.12893.
BibTeX
@article{matthias2016Newper,
title = {New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation},
author = {Matthias Waldner and Daniel Fantus and Mario G. Solari and Angus W. Thomson},
journal = {British Journal of Clinical Pharmacology},
year = {2016},
doi = {10.1111/bcp.12893},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
British Journal of Clinical Pharmacology 2016
Preprint · OA
Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes
Biochemical Society Transactions 2013
Citation only
Adaptation to chronic mTOR inhibition in cancer and in aging
Cells 2019
Open access · CC-BY
mTOR: A Cellular Regulator Interface in Health and Disease
Medical Research Archives 2025
Open access · CC-BY
Beyond Rapamycin: Metadichol Represents a New Class of Multi-Target mTOR Modulators
BMB Reports 2011
Open access · CC-BY
The functions of mTOR in ischemic diseases
Oncotarget 2010
Open access · OA